Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis: Protocol for RIAlta Phase 2b/c Trial

Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis: Protocol for RIAlta Phase 2b/c Trial

Previous clinical trials for drug-susceptible tuberculosis (DS-TB) have shown that first-line treatment with doses of rifampicin up to 40 mg/kg are safe and increase the early treatment response for young adults with pulmonary tuberculosis. This may lead to a shorter treatment duration for those per...

Full description

Bibliographic Details
Main Authors: Juan Espinosa-Pereiro, Samiksha Ghimire, Marieke G. G. Sturkenboom, Jan-Willem C. Alffenaar, Margarida Tavares, Sarita Aguirre, Arturo Battaglia, Gladys Molinas, Teresa Tórtola, Onno W. Akkerman, Adrian Sanchez-Montalva, Cecile Magis-Escurra
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Pharmaceutics
Subjects:
tuberculosis
rifampicin
clinical trial
vulnerable population
Online Access:https://www.mdpi.com/1999-4923/15/1/9

Internet

https://www.mdpi.com/1999-4923/15/1/9

Similar Items